1. Liposomes Combined an Integrin αvβ3-Specific Vector with pH-Responsible Cell-Penetrating Property for Highly Effective Antiglioma Therapy through the Blood–Brain Barrier
   Kairong Shi et al, 2015, ACS Applied Materials & Interfaces CrossRef
2. Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization
   Cathrine Elisabeth Olsen et al, 2019, Journal of Clinical Medicine CrossRef
3. Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy
   Juan Yue et al, 2023, Biomarker Research CrossRef
4. Combination of B7H6-siRNA and Temozolomide Synergistically Reduces Stemness and Migration Properties of Glioblastoma Cancer Cells: Promising Combination Treatment Against GBM
   Nadia Allahyarzadeh Khiabani et al, SSRN Electronic Journal CrossRef
5. Targeting tumour markers in ovarian cancer treatment
   Subham Preetam et al, 2024, Clinica Chimica Acta CrossRef
6. Wnt/β-catenin signaling pathway inhibits the proliferation and apoptosis of U87 glioma cells via different mechanisms
   Liyang Gao et al, 2017, PLOS ONE CrossRef
7. Cancer stem cells: advances in knowledge and implications for cancer therapy
   Xianjing Chu et al, 2024, Signal Transduction and Targeted Therapy CrossRef
8. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response
   Sabine Hombach-Klonisch et al, 2018, Pharmacology & Therapeutics CrossRef
9. Development a hyaluronic acid ion-pairing liposomal nanoparticle for enhancing anti-glioma efficacy by modulating glioma microenvironment
   Liuqing Yang et al, 2018, Drug Delivery CrossRef
10. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment
    Lakshmi Pallavi Ganipineni et al, 2018, Journal of Controlled Release CrossRef
11. Glioblastoma therapy: State of the field and future prospects
    Nadia Allahyarzadeh Khiabani et al, 2024, Life Sciences CrossRef
12. Evaluation of cancer stemness in breast cancer and glioblastoma spheroids in vitro
    Açelya Yilmazer, 2018, 3 Biotech CrossRef
13. Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry
    Shunsuke Itai et al, 2017, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
14. The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection
    Alisa Gisina et al, 2024, Biology CrossRef
15. All-Trans Retinoic Acid Fosters the Multifarious U87MG Cell Line as a Model of Glioblastoma
    Markéta Pokorná et al, 2021, Brain Sciences CrossRef
16. Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells
    Nadia Allahyarzadeh Khiabani et al, 2023, Experimental Cell Research CrossRef
17. PC3-Secreted Microprotein Is Expressed in Glioblastoma Stem-Like Cells and Human Glioma Tissues
    Masato Maruyama et al, 2021, Biological and Pharmaceutical Bulletin CrossRef
18. Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance
    Amir Barzegar Behrooz et al, 2022, Drug Delivery and Translational Research CrossRef
19. The Impact of Non-Lethal Single-Dose Radiation on Tumor Invasion and Cytoskeletal Properties
    Tim Hohmann et al, 2017, International Journal of Molecular Sciences CrossRef
20. Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons
    Alisa Gisina et al, 2023, International Journal of Molecular Sciences CrossRef